首页> 外文OA文献 >The behavior of vascular smooth muscle cells and platelets onto epigallocatechin gallate-releasing poly(l-lactide-co-ε-caprolactone) as stent-coating materials
【2h】

The behavior of vascular smooth muscle cells and platelets onto epigallocatechin gallate-releasing poly(l-lactide-co-ε-caprolactone) as stent-coating materials

机译:血管平滑肌细胞和血小板在释放表没食子儿茶素没食子酸酯的聚(l-丙交酯-co-ε-己内酯)作为支架涂层材料上的行为

代理获取
本网站仅为用户提供外文OA文献查询和代理获取服务,本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文,但由于OA文献来源多样且变更频繁,仍可能出现获取不到、文献不完整或与标题不符等情况,如果获取不到我们将提供退款服务。请知悉。

摘要

Localized drug delivery from drug-eluting stents has been accepted as one of the most promising treatment methods for preventing restenosis after stenting. However, thrombosis, inflammation, and restenosis are still major problems for the utility of cardiovascular prostheses such as vascular grafts and stents. Epigallocatechin-3-O-gallate (EGCG), a major polyphenolic constituent of green tea, has been shown to have anti-thrombotic, anti-inflammatory and anti-proliferative activities. It was hypothesized that controlled release of EGCG from biodegradable poly(lactide-co-ε-caprolactone, PLCL) stent coatings would suppress migration and invasion of vascular smooth muscle cells (VSMCs) as well as platelet-mediated thrombosis. EGCG-releasing PLCL (E-PLCL) was prepared by blending PLCL with 5% EGCG. The surface morphology, roughness and melting temperature of PLCL were not changed despite EGCG addition. EGCG did, however, EGCG appreciably increase the hydrophilicity of PLCL. EGCG was found to be uniformly dispersed throughout E-PLCL without direct chemical interactions with PLCL. E-PLCL displayed diffusion controlled release of EGCG release for periods up to 34 days. E-PLCL significantly suppressed the migration and invasion of VSMCs as well as the adhesion and activation of platelets. E-PLCL coatings were able to smooth the surface of bare stents with neither cracks nor webbings after balloon expansion. The structural integrity of coatings was sufficient to resist delamination or destruction during 90% dilatation. These results suggest that EGCG-releasing polymers can be effectively applied for fabricating an EGCG-eluting vascular stent to prevent in-stent restenosis and thrombosis.
机译:从药物洗脱支架中进行局部给药已被认为是预防支架置入后再狭窄的最有希望的治疗方法之一。然而,血栓形成,炎症和再狭窄仍然是使用诸如血管移植物和支架之类的心血管假体的主要问题。 Epigallocatechin-3-O-gallate(EGCG)是绿茶的主要多酚成分,已被证明具有抗血栓形成,抗炎和抗增殖的作用。假设从可生物降解的聚(丙交酯-ε-己内酯,PLCL)支架涂层中控制释放EGCG会抑制血管平滑肌细胞(VSMC)的迁移和侵袭以及血小板介导的血栓形成。通过将PLCL与5%EGCG混合来制备释放EGCG的PLCL(E-PLCL)。尽管添加了EGCG,PLCL的表面形态,粗糙度和熔化温度均未改变。但是,EGCG确实明显增加了PLCL的亲水性。发现EGCG均匀地分散在整个E-PLCL中,而没有与PLCL的直接化学相互作用。 E-PLCL显示EGCG释放的扩散控制释放长达34天。 E-PLCL显着抑制了VSMC的迁移和侵袭以及血小板的粘附和活化。气囊膨胀后,E-PLCL涂层能够使裸露的支架表面光滑,既没有裂纹也没有带子。涂层的结构完整性足以抵抗90%的膨胀过程中的分层或破坏。这些结果表明,释放EGCG的聚合物可以有效地用于制造洗脱EGCG的血管支架,以防止支架内再狭窄和血栓形成。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
代理获取

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号